| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8736380 | Autoimmunity Reviews | 2018 | 22 Pages |
Abstract
Our personal data and pooled literature analysis suggest the efficacy of rituximab in the subset of diffuse SSc in particular in skin and interstitial disease involvements. The safety of rituximab seems to be reasonable and similar to previous data in other autoimmune diseases.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Mathilde Thiebaut, David Launay, Sébastien Rivière, Thibault Mahévas, Syrine Bellakhal, Eric Hachulla, Olivier Fain, Arsène Mekinian,